Cargando…
The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State
BACKGROUND: Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for buprenorphine have high barriers for initiation and retention. Health care and drug...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261214/ https://www.ncbi.nlm.nih.gov/pubmed/35799210 http://dx.doi.org/10.1186/s13722-022-00315-4 |
_version_ | 1784742223564242944 |
---|---|
author | Banta-Green, Caleb J. Owens, Mandy D. Williams, Jason R. Sears, Jeanne M. Floyd, Anthony S. Williams-Gilbert, Wendy Kingston, Susan |
author_facet | Banta-Green, Caleb J. Owens, Mandy D. Williams, Jason R. Sears, Jeanne M. Floyd, Anthony S. Williams-Gilbert, Wendy Kingston, Susan |
author_sort | Banta-Green, Caleb J. |
collection | PubMed |
description | BACKGROUND: Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for buprenorphine have high barriers for initiation and retention. Health care and drug treatment systems have not been able to provide services to all—let alone the majority—who need it, and many with OUD report extreme challenges starting and staying on buprenorphine in those care settings. We describe the design and protocol for a study of a rapid access buprenorphine program model in six Washington State communities at existing sites serving people who are unhoused and/or using syringe services programs. This study aimed to test the effectiveness of a Community-Based Medication-First Program model. METHODS: We are conducting a hybrid effectiveness-implementation study of a rapid access buprenorphine model of care staffed by prescribers, nurse care managers, and care navigators. The Community-Based Medication-First model of care was designed as a 6-month, induction-stabilization-transition model to be delivered between 2019 and 2022. Effectiveness outcomes will be tested by comparing the intervention group with a comparison group derived from state records of people who had OUD. Construction of the comparison group will align characteristics such as geography, demographics, historical rates of arrests, OUD medication, and health care utilization, using restriction and propensity score techniques. Outcomes will include arrests, emergency and inpatient health care utilization, and mortality rates. Descriptive statistics for buprenorphine utilization patterns during the intervention period will be documented with the prescription drug monitoring program. DISCUSSION: Results of this study will help determine the effectiveness of the intervention. Given the serious population-level and individual-level impacts of OUD, it is essential that services be readily available to all people with OUD, including those who cannot readily access care due to their circumstances, capacity, preferences, and related systems barriers. |
format | Online Article Text |
id | pubmed-9261214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92612142022-07-07 The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State Banta-Green, Caleb J. Owens, Mandy D. Williams, Jason R. Sears, Jeanne M. Floyd, Anthony S. Williams-Gilbert, Wendy Kingston, Susan Addict Sci Clin Pract Study Protocol BACKGROUND: Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine. Many access points for buprenorphine have high barriers for initiation and retention. Health care and drug treatment systems have not been able to provide services to all—let alone the majority—who need it, and many with OUD report extreme challenges starting and staying on buprenorphine in those care settings. We describe the design and protocol for a study of a rapid access buprenorphine program model in six Washington State communities at existing sites serving people who are unhoused and/or using syringe services programs. This study aimed to test the effectiveness of a Community-Based Medication-First Program model. METHODS: We are conducting a hybrid effectiveness-implementation study of a rapid access buprenorphine model of care staffed by prescribers, nurse care managers, and care navigators. The Community-Based Medication-First model of care was designed as a 6-month, induction-stabilization-transition model to be delivered between 2019 and 2022. Effectiveness outcomes will be tested by comparing the intervention group with a comparison group derived from state records of people who had OUD. Construction of the comparison group will align characteristics such as geography, demographics, historical rates of arrests, OUD medication, and health care utilization, using restriction and propensity score techniques. Outcomes will include arrests, emergency and inpatient health care utilization, and mortality rates. Descriptive statistics for buprenorphine utilization patterns during the intervention period will be documented with the prescription drug monitoring program. DISCUSSION: Results of this study will help determine the effectiveness of the intervention. Given the serious population-level and individual-level impacts of OUD, it is essential that services be readily available to all people with OUD, including those who cannot readily access care due to their circumstances, capacity, preferences, and related systems barriers. BioMed Central 2022-07-07 2022 /pmc/articles/PMC9261214/ /pubmed/35799210 http://dx.doi.org/10.1186/s13722-022-00315-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Banta-Green, Caleb J. Owens, Mandy D. Williams, Jason R. Sears, Jeanne M. Floyd, Anthony S. Williams-Gilbert, Wendy Kingston, Susan The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title | The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title_full | The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title_fullStr | The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title_full_unstemmed | The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title_short | The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State |
title_sort | community-based medication-first program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in washington state |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261214/ https://www.ncbi.nlm.nih.gov/pubmed/35799210 http://dx.doi.org/10.1186/s13722-022-00315-4 |
work_keys_str_mv | AT bantagreencalebj thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT owensmandyd thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT williamsjasonr thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT searsjeannem thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT floydanthonys thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT williamsgilbertwendy thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT kingstonsusan thecommunitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT bantagreencalebj communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT owensmandyd communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT williamsjasonr communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT searsjeannem communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT floydanthonys communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT williamsgilbertwendy communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate AT kingstonsusan communitybasedmedicationfirstprogramforopioidusedisorderahybridimplementationstudyprotocolofarapidaccesstobuprenorphineprograminwashingtonstate |